FDA approves Topicort Topical Spray
HAWTHORNE, NY: Taro Pharmaceutical Industries Ltd. reported last week that it has received approval from the U.S. Food and Drug Administration for its New Drug Application Topicort (desoximetasone) Topical Spray, 0.25%.
Topicort Topical Spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
According to industry sources, the corticosteroid spray market is approximately $100 million in annual sales in the U.S.
Taro Pharmaceutical Industries is a multinational, science-based pharmaceutical company. For further information on Taro, visit its website at Taro.com.